Prevention and Treatment of Cancer Therapeutics-related Cardiac Dysfunction.
10.3881/j.issn.1000-503X.11380
- Author:
Wen Guang CHEN
1
;
Lin ZHAO
1
Author Information
1. Department of Medical Oncology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
- Publication Type:Journal Article
- Keywords:
anti-tumor drugs;
cardiac dysfunction;
cardiac function monitoring
- MeSH:
Cardiotoxicity;
Heart;
Heart Diseases;
Humans
- From:
Acta Academiae Medicinae Sinicae
2019;41(6):842-850
- CountryChina
- Language:Chinese
-
Abstract:
Cancer therapeutics-related cardiac dysfunction(CTRCD)is receiving more attention.Risk factors assessment before cancer therapy,cardiac function monitoring during and after cancer therapy,and early detection and treatment of myocardial injury are key to preventing clinical heart failure.The incidence and severity of cardiotoxicity can be reduced by measures such as reducing drug dose,adjusting administration route,and using low toxic drugs.Cardioprotective agents including anti-heart failure drugs and dexrazoxane are important for the prevention and treatment of CTRCD.Patients with advanced heart failure may also benefit from mechanical treatments including cardiac resynchronization therapy and mechanically-assisted ventricular devices.This article reviews the recent advances in the prevention and treatment of CTRCD.
